Summary of BridgeBio Oncology Therapeutics FY Conference Call Company Overview - **Company**: BridgeBio Oncology Therapeutics (NasdaqGM:BBOT) - **Key Speakers**: CEO Eli Wallace, CFO Uneek Mehra Key Accomplishments in 2025 - Progressed all three clinical programs discovered in-house targeting RAS and PI3K alpha oncogenes [7][9] - Successfully completed a de-SPAC merger with Helix2, raising approximately $380 million with only 39% redemptions [9] - Established a strong foundation for 2026 with upcoming data readouts for all three programs [10] Clinical Programs and Data 1. **BBO-8520 (G12C Inhibitor)** - Achieved a 60% confirmed overall response rate in early clinical data [17] - Demonstrated a differentiated safety profile with no grade three toxicities and no liver enzyme changes [17][18] - Anticipated data readout in Q1 2026, focusing on monotherapy efficacy and safety [20] 2. **BBO-10203 (RAS PI3K Alpha Breaker)** - Unique mechanism that inhibits RAS-dependent activation of PI3K alpha without affecting glucose homeostasis [23][24] - Ongoing clinical trial with no restrictions on HbA1c status for patient entry [24] - Expected to show differentiated safety and efficacy data in the first half of 2026 [27] 3. **BBO-11818 (Pan-KRAS Inhibitor)** - Designed to selectively inhibit KRAS mutations while sparing H and N RAS, potentially leading to better therapeutic outcomes [31][32] - Data expected in the second half of 2026, focusing on various tumor types [33] Strategic Focus and Market Position - RAS is a critical target, with approximately 30% of human tumors having mutations in RAS [14] - The company aims to differentiate itself through innovative approaches to targeting RAS and PI3K pathways [16][25] - Plans to evaluate the entire portfolio based on upcoming data to prioritize programs for further development [21][38] Future Directions - Potential for strategic partnerships based on data outcomes and capital needs [39] - Ongoing research for additional follow-on assets, indicating a commitment to expanding the pipeline [43][44] Conclusion - BridgeBio Oncology is positioned to make significant advancements in the treatment of RAS-driven tumors with its innovative drug candidates and strategic planning for future data releases and partnerships [38][40]